Australia markets closed

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.45-0.03 (-0.55%)
At close: 04:00PM EDT
5.38 -0.07 (-1.28%)
After hours: 04:08PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 146.47M
Enterprise value 99.84M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)24.42
Price/book (mrq)9.73
Enterprise value/revenue 14.30
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 337.00%
S&P500 52-week change 326.36%
52-week high 38.17
52-week low 32.09
50-day moving average 35.50
200-day moving average 34.88

Share statistics

Avg vol (3-month) 3197.24k
Avg vol (10-day) 3103.08k
Shares outstanding 526.73M
Implied shares outstanding 626.73M
Float 812.56M
% held by insiders 11.32%
% held by institutions 184.94%
Shares short (30 Apr 2024) 41.45M
Short ratio (30 Apr 2024) 46.12
Short % of float (30 Apr 2024) 45.91%
Short % of shares outstanding (30 Apr 2024) 45.43%
Shares short (prior month 28 Mar 2024) 41.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 319 Sept 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,778.97%

Management effectiveness

Return on assets (ttm)-45.66%
Return on equity (ttm)-237.24%

Income statement

Revenue (ttm)6.98M
Revenue per share (ttm)0.22
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -122.26M
Net income avi to common (ttm)-144.49M
Diluted EPS (ttm)-5.06
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)108.3M
Total cash per share (mrq)4.05
Total debt (mrq)61.67M
Total debt/equity (mrq)409.58%
Current ratio (mrq)3.01
Book value per share (mrq)0.56

Cash flow statement

Operating cash flow (ttm)-103.9M
Levered free cash flow (ttm)-60.57M